glycine has been researched along with Glioblastoma in 13 studies
Glioblastoma: A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here, we find that serine and glycine levels were higher in low-nutrient regions of tumors in glioblastoma multiforme (GBM) patients than they were in other regions." | 4.02 | Glioma cells require one-carbon metabolism to survive glutamine starvation. ( Bamba, T; Fujita, Y; Hashiguchi, M; Hosoda, K; Irino, Y; Izumi, Y; Kitta, A; Kohmura, E; Kohta, M; Kyotani, K; Nagashima, H; Nakai, T; Sasayama, T; Satoh, N; Shinohara, M; Takahashi, M; Tanaka, K; Uno, T; Uozumi, Y, 2021) |
| " Here, we report that RGS loaded in apolipoprotein E derived peptide (ApoE)-targeted chimaeric polymersomes (ApoE-CP) is safe and highly potent against human GBM in vivo." | 1.51 | Oncoprotein Inhibitor Rigosertib Loaded in ApoE-Targeted Smart Polymersomes Reveals High Safety and Potency against Human Glioblastoma in Mice. ( Deng, C; Jiang, Y; Qin, H; Zhang, J; Zhong, Z, 2019) |
| "Glycine was detected in 24% of all studies, though with a wide range of signal amplitude and extent of the spatial distributions." | 1.40 | Mapping of glycine distributions in gliomas. ( Behari, S; Gupta, RK; Hussain, N; Maudsley, AA; Parra, NA; Roy, B; Sheriff, S; Stoyanova, R, 2014) |
| "Glioblastomas and brain metastases demonstrate avid uptake of 2-[(18) F]fluoro-2-deoxyglucose by positron emission tomography and display perturbations of intracellular metabolite pools by (1) H MRS." | 1.38 | Metabolism of [U-13 C]glucose in human brain tumors in vivo. ( Bachoo, RM; Choi, C; DeBerardinis, RJ; Hatanpaa, KJ; Jeffrey, FM; Jindal, A; Madden, C; Maher, EA; Malloy, CR; Marin-Valencia, I; Mashimo, T; Mathews, D; Mickey, BE; Pascual, JM; Raisanen, J, 2012) |
| "Glycine is a key metabolic intermediate required for the synthesis of proteins, nucleic acids, and other molecules, and its detection in cancer could, therefore, provide biologically relevant information about the growth of the tumor." | 1.37 | Measurement of glycine in the human brain in vivo by 1H-MRS at 3 T: application in brain tumors. ( Bachoo, R; Choi, C; DeBerardinis, RJ; Dimitrov, IE; Ganji, SK; Maher, EA; Malloy, CR; Mickey, BE; Pascual, JM, 2011) |
| "Using 36 biopsies from patients with brain tumors [12 glioblastoma multiforme (GBM); 10 low-grade (LG), including 7 schwannoma and 3 pylocytic astrocytoma; 7 meningioma (MN); 7 brain metastases (MT), including 3 adenocarcinoma and 4 breast cancer] and 9 control biopsies from patients undergoing surgery for epilepsy, we tested the hypothesis that the presence of glycine may distinguish among these brain tumor types." | 1.36 | High-resolution magic angle spinning magnetic resonance spectroscopy detects glycine as a biomarker in brain tumors. ( Andronesi, OC; Black, PM; Mintzopoulos, D; Righi, V; Tzika, AA, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 3 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Su, X | 1 |
| Xie, Y | 1 |
| Zhang, J | 2 |
| Li, M | 1 |
| Zhang, Q | 1 |
| Jin, G | 1 |
| Liu, F | 1 |
| Chorsi, MT | 1 |
| Le, TT | 1 |
| Lin, F | 1 |
| Vinikoor, T | 1 |
| Das, R | 1 |
| Stevens, JF | 1 |
| Mundrane, C | 1 |
| Park, J | 1 |
| Tran, KTM | 1 |
| Liu, Y | 1 |
| Pfund, J | 1 |
| Thompson, R | 1 |
| He, W | 1 |
| Jain, M | 1 |
| Morales-Acosta, MD | 1 |
| Bilal, OR | 1 |
| Kazerounian, K | 1 |
| Ilies, H | 1 |
| Nguyen, TD | 1 |
| Tanaka, K | 1 |
| Sasayama, T | 1 |
| Nagashima, H | 1 |
| Irino, Y | 1 |
| Takahashi, M | 1 |
| Izumi, Y | 1 |
| Uno, T | 1 |
| Satoh, N | 1 |
| Kitta, A | 1 |
| Kyotani, K | 1 |
| Fujita, Y | 1 |
| Hashiguchi, M | 1 |
| Nakai, T | 1 |
| Kohta, M | 1 |
| Uozumi, Y | 1 |
| Shinohara, M | 1 |
| Hosoda, K | 1 |
| Bamba, T | 1 |
| Kohmura, E | 1 |
| Voon, HPJ | 1 |
| Udugama, M | 1 |
| Lin, W | 1 |
| Hii, L | 1 |
| Law, RHP | 1 |
| Steer, DL | 1 |
| Das, PP | 1 |
| Mann, JR | 1 |
| Wong, LH | 1 |
| Qin, H | 1 |
| Jiang, Y | 1 |
| Deng, C | 1 |
| Zhong, Z | 1 |
| Maudsley, AA | 1 |
| Gupta, RK | 1 |
| Stoyanova, R | 1 |
| Parra, NA | 1 |
| Roy, B | 1 |
| Sheriff, S | 1 |
| Hussain, N | 1 |
| Behari, S | 1 |
| Kim, D | 1 |
| Fiske, BP | 1 |
| Birsoy, K | 1 |
| Freinkman, E | 1 |
| Kami, K | 1 |
| Possemato, RL | 1 |
| Chudnovsky, Y | 1 |
| Pacold, ME | 1 |
| Chen, WW | 1 |
| Cantor, JR | 1 |
| Shelton, LM | 1 |
| Gui, DY | 1 |
| Kwon, M | 1 |
| Ramkissoon, SH | 1 |
| Ligon, KL | 1 |
| Kang, SW | 1 |
| Snuderl, M | 1 |
| Vander Heiden, MG | 1 |
| Sabatini, DM | 1 |
| Righi, V | 1 |
| Andronesi, OC | 1 |
| Mintzopoulos, D | 1 |
| Black, PM | 1 |
| Tzika, AA | 1 |
| Choi, C | 2 |
| Ganji, SK | 1 |
| DeBerardinis, RJ | 2 |
| Dimitrov, IE | 1 |
| Pascual, JM | 2 |
| Bachoo, R | 1 |
| Mickey, BE | 2 |
| Malloy, CR | 2 |
| Maher, EA | 2 |
| Marin-Valencia, I | 1 |
| Bachoo, RM | 1 |
| Mashimo, T | 1 |
| Raisanen, J | 1 |
| Hatanpaa, KJ | 1 |
| Jindal, A | 1 |
| Jeffrey, FM | 1 |
| Madden, C | 1 |
| Mathews, D | 1 |
| Gessi, M | 1 |
| Gielen, GH | 1 |
| Hammes, J | 1 |
| Dörner, E | 1 |
| Mühlen, AZ | 1 |
| Waha, A | 1 |
| Pietsch, T | 1 |
| Hagberg, G | 1 |
| Burlina, AP | 1 |
| Mader, I | 1 |
| Roser, W | 1 |
| Radue, EW | 1 |
| Seelig, J | 1 |
| Gomeza, J | 1 |
| Zafra, F | 1 |
| Olivares, L | 1 |
| Giménez, C | 1 |
| Aragón, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment Development of Triheptanoin for Glucose Transporter Type I Deficiency[NCT02021526] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2015-12-31 | Withdrawn (stopped due to NIH funding resulted in new clinical trial) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 other studies available for glycine and Glioblastoma
| Article | Year |
|---|---|
HIF-α activation by the prolyl hydroxylase inhibitor roxadustat suppresses chemoresistant glioblastoma growth by inducing ferroptosis.
Topics: Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Ferr | 2022 |
Highly piezoelectric, biodegradable, and flexible amino acid nanofibers for medical applications.
Topics: Amino Acids; Animals; Brain; Glioblastoma; Glycine; Mice; Nanofibers | 2023 |
Glioma cells require one-carbon metabolism to survive glutamine starvation.
Topics: Aminohydrolases; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Ge | 2021 |
Inhibition of a K9/K36 demethylase by an H3.3 point mutation found in paediatric glioblastoma.
Topics: Animals; Arginine; Biotinylation; Brain Neoplasms; Child; Chromatin; Disease Models, Animal; Embryon | 2018 |
Oncoprotein Inhibitor Rigosertib Loaded in ApoE-Targeted Smart Polymersomes Reveals High Safety and Potency against Human Glioblastoma in Mice.
Topics: Animals; Antineoplastic Agents; Apolipoproteins E; Blood-Brain Barrier; Brain Neoplasms; Cell Line, | 2019 |
Mapping of glycine distributions in gliomas.
Topics: Adolescent; Adult; Aged; Astrocytoma; Brain; Brain Mapping; Brain Neoplasms; Choline; Diffusion Magn | 2014 |
SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance.
Topics: Acetone; Animals; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Female; Glioblasto | 2015 |
High-resolution magic angle spinning magnetic resonance spectroscopy detects glycine as a biomarker in brain tumors.
Topics: Adolescent; Adult; Biomarkers, Tumor; Brain Neoplasms; Glioblastoma; Glycine; Humans; Inositol; Magn | 2010 |
Measurement of glycine in the human brain in vivo by 1H-MRS at 3 T: application in brain tumors.
Topics: Brain Chemistry; Brain Neoplasms; Glioblastoma; Glycine; Humans; Imaging, Three-Dimensional; Inosito | 2011 |
Metabolism of [U-13 C]glucose in human brain tumors in vivo.
Topics: Acetyl Coenzyme A; Blood Glucose; Brain Neoplasms; Breast Neoplasms; Carbon Isotopes; Carcinoma, Non | 2012 |
H3.3 G34R mutations in pediatric primitive neuroectodermal tumors of central nervous system (CNS-PNET) and pediatric glioblastomas: possible diagnostic and therapeutic implications?
Topics: Adolescent; Arginine; Central Nervous System Neoplasms; Child; Child, Preschool; DNA Mutational Anal | 2013 |
In vivo proton MR spectroscopy of human gliomas: definition of metabolic coordinates for multi-dimensional classification.
Topics: Adult; Aspartic Acid; Astrocytoma; Brain Neoplasms; Choline; Cluster Analysis; Creatine; Discriminan | 1995 |
Regulation by phorbol esters of the glycine transporter (GLYT1) in glioblastoma cells.
Topics: Alkaloids; Amino Acid Transport Systems, Neutral; Animals; Base Sequence; Biological Transport; Carr | 1995 |